Press Release

« Back
Printer Friendly Version View printer-friendly version
Exelixis Announces March 9 Webcast of Its Fourth Quarter and Full Year 2009 Financial Results Conference Call
SOUTH SAN FRANCISCO, Calif., Mar 02, 2010 (BUSINESS WIRE) -- Exelixis, Inc. (Nasdaq:EXEL) will release its fourth quarter and full year 2009 financial results on Tuesday, March 9, 2010 before the markets open. The announcement will be followed by a live webcast at 8:00 a.m. ET/ 5:00 a.m. PT, in which Exelixis management will discuss the company's financial results, financial outlook and corporate strategy, and provide a general business update. The webcast may be accessed in the Event Calendar page under Investors at

An audio replay of the webcast will be available until 11:59 p.m. ET/ 8:59 p.m. PT on April 9, 2010. Access numbers for the replay are: 1-888-286-8010 (domestic) and 1-617-801-6888 (international), and the passcode is 15744931.

About Exelixis

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 3, phase 2, and phase 1 clinical development. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including Bristol-Myers Squibb, sanofi-aventis, GlaxoSmithKline, Genentech (a wholly owned member of the Roche Group), Boehringer Ingelheim, Pfizer Inc., and Daiichi-Sankyo. For more information, please visit the company's web site at

Exelixis and the Exelixis logo are registered U.S. trademarks.

SOURCE: Exelixis, Inc.

Exelixis, Inc.
Investor Contacts:
Charles Butler, 650-837-7277
Vice President, Investor Relations and Corporate Communications
DeDe Sheel, 650-837-8231
Associate Director, Investor Relations